全球癌症疼痛市場規模、佔有率、成長分析（按藥物、適應症分類）- 2024-2031 年產業預測

Global Cancer Pain Market Size, Share, Growth Analysis, By Drug(Opioids, Morphine), By Disease Indication(Lung Cancer, Colorectal Cancer) - Industry Forecast 2024-2031

出版日期: 2024年03月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球癌症疼痛市場規模為65.5億美元，預計將從2023年的 69.2 億美元成長到2031年的 107 億美元，預測期內（2024-2031年）年複合成長率為 5.6%。

由於受癌症影響的人數不斷增加、人口老化、醫療保健投入增加，全球癌症疼痛市場成長，部分原因是護理公司進行更多研究。例如，根據美國癌症協會的資料，2020年，美國約有 180 萬新發癌症病例，約 606,520 人死於癌症。根據國際癌症研究機構統計，當年全球約有 1,065,960 人新診斷出罹患大腸癌。由於老齡化對身體和基因變化的影響，老年人更容易罹患癌症。根據美國國家癌症研究所的資料，乳癌的平均診斷年齡為 61 歲，大腸癌的平均診斷年齡為 68 歲，肺癌的平均診斷年齡為 70 歲，而攝護腺癌的平均診斷年齡為 66 歲。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭形勢

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

Pfizer（USA）
Johnson & Johnson（USA）
Purdue Pharma（USA）
Novartis（Switzerland）
Heron Therapeutics（USA）
Teva Pharmaceutical Industries（Israel）
Eli Lilly and Company（USA）
AstraZeneca（UK）
GlaxoSmithKline（UK）
Merck & Co., Inc.（USA）

簡介目錄

Product Code: SQMIG35J2075

Global Cancer Pain Market size was valued at USD 6.55 billion in 2022 and is poised to grow from USD 6.92 billion in 2023 to USD 10.70 billion by 2031, growing at a CAGR of 5.6% in the forecast period (2024-2031).

The global cancer pain market is growing because there are more people getting cancer, the population is getting older, more money is being spent on healthcare, and healthcare companies are doing more research. For example, in 2020, the American Cancer Society said there were about 1.8 million new cases of cancer and around 606,520 people died from cancer in the U.S. That same year, there were about 1,065,960 new cases of colorectal cancer worldwide, according to the International Agency for Research on Cancer. Older people are more likely to get cancer because of how aging affects the body and changes in genes. The National Cancer Institute says the average age for diagnosing breast cancer is 61, colorectal cancer is 68, lung cancer is 70, and prostate cancer is 66.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Pain Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Pain Market Segmental Analysis

The global cancer pain market is segmented on the basis of drug type, disease indication, region. By drug type, the market is segmented into opioids, morphine, fentanyl, others, non-opioids, acetaminophen, non-steroidal anti-inflammatory drugs (nsaids), nerve blockers. By disease indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global Cancer Pain Market

New ways of managing pain, better ways to give medicine, and treatments made just for each person are making cancer pain management work better and be easier to get to.

Restraints in the Global Cancer Pain Market

The possibility of getting used to a drug, needing it more, and having side effects from pain medicines can stop the market from growing.

Market Trends of the Global Cancer Pain Market

More attention is being put on treating each person differently based on their genes and molecules, which is changing how cancer pain is managed.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Cancer Pain Market by Drug

Market Overview
Opioids
Morphine
Fentanyl
Others
Non-opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

Global Cancer Pain Market by Disease Indication

Market Overview
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Blood Cancer
Others

Global Cancer Pain Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Purdue Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heron Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA0
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments